Tags

Type your tag names separated by a space and hit enter

Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway.
Cells. 2021 01 25; 10(2)C

Abstract

Parkinson's disease (PD) is one of the major neurodegenerative diseases (ND) which presents a progressive neurodegeneration characterized by loss of dopamine in the substantia nigra pars compacta. It is well known that oxidative stress, inflammation and glutamatergic pathway play key roles in the development of PD. However, therapies remain uncertain and research for new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on PD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3beta, the main inhibitor of the WNT/β-catenin pathway. The stimulation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in PD.

Authors+Show Affiliations

Department of Clinical Research and Innovation (DRCI), Hôpital Foch, 92150 Suresnes, France.Centre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules Verne (UPJV), 80054 Amiens, France. Laboratoire de Mathématiques et Applications (LMA), UMR CNRS 7348, Université de Poitiers, 86021 Poitiers, France.Centre de Recherche Clinique, Grand Hôpital de l'Est Francilien (GHEF), 6-8 rue Saint-Fiacre, 77100 Meaux, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33503974

Citation

Vallée, Alexandre, et al. "Parkinson's Disease: Potential Actions of Lithium By Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway." Cells, vol. 10, no. 2, 2021.
Vallée A, Vallée JN, Lecarpentier Y. Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. Cells. 2021;10(2).
Vallée, A., Vallée, J. N., & Lecarpentier, Y. (2021). Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. Cells, 10(2). https://doi.org/10.3390/cells10020230
Vallée A, Vallée JN, Lecarpentier Y. Parkinson's Disease: Potential Actions of Lithium By Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. Cells. 2021 01 25;10(2) PubMed PMID: 33503974.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. AU - Vallée,Alexandre, AU - Vallée,Jean-Noël, AU - Lecarpentier,Yves, Y1 - 2021/01/25/ PY - 2020/11/25/received PY - 2021/01/04/revised PY - 2021/01/08/accepted PY - 2021/1/28/entrez PY - 2021/1/29/pubmed PY - 2021/10/16/medline KW - Parkinson KW - WNT/beta-catenin pathway KW - glutamatergic pathway KW - inflammation KW - lithium KW - oxidative stress JF - Cells JO - Cells VL - 10 IS - 2 N2 - Parkinson's disease (PD) is one of the major neurodegenerative diseases (ND) which presents a progressive neurodegeneration characterized by loss of dopamine in the substantia nigra pars compacta. It is well known that oxidative stress, inflammation and glutamatergic pathway play key roles in the development of PD. However, therapies remain uncertain and research for new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on PD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3beta, the main inhibitor of the WNT/β-catenin pathway. The stimulation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in PD. SN - 2073-4409 UR - https://www.unboundmedicine.com/medline/citation/33503974/Parkinson's_Disease:_Potential_Actions_of_Lithium_by_Targeting_the_WNT/��_Catenin_Pathway_Oxidative_Stress_Inflammation_and_Glutamatergic_Pathway_ L2 - https://www.mdpi.com/resolver?pii=cells10020230 DB - PRIME DP - Unbound Medicine ER -